For-Robin (F-R) is an antibody immunotherapy development company. Specifically, F-R is developing therapies around its monoclonal antibody JAA-F11, focusing first on the breast cancer market. JAA-F11 was discovered and developed by Dr. Kate Rittenhouse Olson, the founder and Chief Scientific Officer of F-R.JAA-F11 binds to the Thomsen-Friedenreich glycoantigen (TF-Ag), a disaccharide tumor marker. TF-Ag is expressed on the surface of about 80% of carcinomas including those of the breast, colon and prostate. Of significance, TF-Ag is not accessible on normal tissues. Thus, JAA-F11 is highly selective, targeting the TF-Ag antigen found on cancer cells. JAA-F11 has been tested and reacts with 77% of human breast cancers (including triple negative breast cancers) and about 60% of the colon, prostate and ovarian cancers tested. It has been used to successfully image human tumors in a SCID mouse model, and has been shown to block a key step in metastasis of human breast, colon and prosta...
For-Robin (F-R) is an antibody immunotherapy development company. Specifically, F-R is developing therapies around its monoclonal antibody JAA-F11, focusing first on the breast cancer market. JAA-F11 was discovered and developed by Dr. Kate Rittenhouse Olson, the founder and Chief Scientific Officer of F-R.JAA-F11 binds to the Thomsen-Friedenreich glycoantigen (TF-Ag), a disaccharide tumor marker. TF-Ag is expressed on the surface of about 80% of carcinomas including those of the breast, colon and prostate. Of significance, TF-Ag is not accessible on normal tissues. Thus, JAA-F11 is highly selective, targeting the TF-Ag antigen found on cancer cells. JAA-F11 has been tested and reacts with 77% of human breast cancers (including triple negative breast cancers) and about 60% of the colon, prostate and ovarian cancers tested. It has been used to successfully image human tumors in a SCID mouse model, and has been shown to block a key step in metastasis of human breast, colon and prostate tumor cells. Internalization studies, which are key to the use of JAA-F11as an antibody drug conjugate, have shown that within one hour, 80% of JAA-F11 is internalized in human tumor cells.

JAA-F11 is owned and patented by the University at Buffalo (Patent number US7374755 B2, filing date July 26, 2005). In 2013, UB entered into an exclusive licensing agreement with For-Robin (F-R) for the purpose of commercializing the monoclonal antibody.
Our business strategy is to develop JAA-F11 to the point where it will be licensed by large pharmaceutical companies. Potential licensees will come from either or both of two specific business areas;
1. Antibody Immunotherapy specifically targeting the treatment of breast, colon, bladder, prostate or other cancers.
2. Antibody Drug Conjugates (ADC) where partner companies seek a highly targeted solution for the delivery of their drugs to tumors.
Antibody therapies are an exploding area of interest for cancer treatment modalities. One Antibody Immunotherapy for breast cancer using Herceptin generated $6.3 billion in worldwide sales in 2012.
Antibody Drug Conjugate (ADC) therapies use a highly selective antibody to target (deliver) a toxic payload to cancer cells. The ADC market saw eight major pharmaceutical companies enter into license agreements with small and early stage companies in the last two years.
More information